Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer

Journal of Nuclear Medicine

Volumn 56, Issue 3, 2015, Pages 372-378

  Sah, Bert Ram ^a   Burger, Irene A ^a   Schibli, Roger ^b,c   Friebe, Matthias ^d   Dinkelborg, Ludger ^d   Graham, Keith ^e   Borkowski, Sandra ^e   Bacher Stier, Claudia ^e   Valencia, Ray ^e   Srinivasan, Ananth ^e   Hany, Thomas F ^a   Mu, Linjing ^a   Wild, Peter J ^a   Schaefer, Niklaus G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d Piramal Enterprises Limited   (India)

^e BAYER PHARMA AG   (Germany)

Author keywords

18F radiolabeled bombesin analogue; Dosimetry; Gastrin releasing peptide; GRP receptor imaging; Prostate cancer

Indexed keywords

BAY 864367 F 18; FLUOROCHOLINE F 18; GASTRIN RELEASING PEPTIDE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRACER; UNCLASSIFIED DRUG; BAY 86-4367; BOMBESIN; FLUORINE; GASTRIN RELEASING PEPTIDE; RADIOPHARMACEUTICAL AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER INFILTRATION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOSIMETRY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXPLORATORY RESEARCH; FALSE POSITIVE RESULT; FIRST IN HUMAN STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TISSUE DISTRIBUTION; ALGORITHM; ANALOGS AND DERIVATIVES; BIOPSY; CHEMISTRY; COMPUTER PROGRAM; DIAGNOSTIC USE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PROCEDURES; PROSTATE TUMOR; RADIOMETRY; SCINTISCANNING; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVENOUS; AGED; ALGORITHMS; BIOPSY; BOMBESIN; FLUORINE RADIOISOTOPES; GASTRIN-RELEASING PEPTIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOPHARMACEUTICALS; SOFTWARE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928162601     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.147116     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Zhang H, Abiraj K, Thorek DL, et al. Evolution of bombesin conjugates for targeted PET imaging of tumors. PLoS ONE. 2012;7:e44046.
3. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549-555.
4. 11C-choline. J Nucl Med. 2011;52:81-89.
5. 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106-117.
6. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. 2013;31:427-435.
7. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833-840.
8. Beer M, Montani M, Gerhardt J, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318-325.
9. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer. 1989;63:1714-1720.
10. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
11. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med. 2011;52:270-278.
12. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
13. 18F]-FEPPA, to image translocator protein (18 kDa). Mol Imaging Biol. 2013;15:353-359.
14. Abiraj K, Mansi R, Tamma ML, et al. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. Chemistry. 2010;16:2115-2124.
15. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240-5249.
16. Schroeder RP, Muller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1386-1396.
17. Linder KE, Metcalfe E, Arunachalam T, et al. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites. Bioconjug Chem. 2009;20:1171-1178.
18. 99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. Q J Nucl Med Mol Imaging. 2007;51:42-50.
19. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med. 2008;49:453-461.
20. 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem. 2009;52:425-432.
21. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009;36:1483-1494.
22. 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med. 2009;50:1168-1177.
23. Yang M, Gao H, Zhou Y, et al. F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2011;1:220-229.
24. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
25. 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-1397.
26. 4]-bombesin analog in human prostate tumor-bearing mice. Cancer Biother Radiopharm. 2009;24:435-443.
27. 64Cu-NOTA-8-Aoc-BBN(7-14) NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA. 2007;104:12462-12467.
28. 64Culabeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52:470-477.
29. 64Culabeled bifunctional chelate-bombesin conjugates. Bioconjug Chem. 2011;22:1729-1735.
30. Lin KS, Luu A, Baidoo KE, et al. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjug Chem. 2005;16:43-50.
31. 99mTc-EDDA/HYNIC-[Lys3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun. 2006;27:371-376.
32. 99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem. 2008;19:2432-2439.
33. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:247-258.
34. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999;36:31-35.
35. 18F-fluorocholine. J Nucl Med. 2002;43:92-96.
36. Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist: from mice to men. Theranostics. 2014;4:412-419.
37. Mansi R, Fleischmann A, Macke HR, Reubi JC. Targeting GRPR in urological cancers: from basic research to clinical application. Nat Rev Urol. 2013;10:235-244.
38. de Visser M, van Weerden WM, de Ridder CM, et al. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med. 2007;48:88-93.
39. 68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434-5443.
40. Körner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014;74:217-224.